Вы искали: prostatectomy (Английский - Словенский)

radical prostatectomy
0, 60 (0, 49 – 0, 73)

watchful waiting radiotherapy radical prostatectomy
radioterapija radikalna prostatektomija

it is not known if tadalafil is effective in patients who have undergone pelvic surgery or radical non-nervesparing prostatectomy.
ni znano, ali je zdravilo tadalafil mylan učinkovito pri bolnikih po operacijah v medenici ali po radikalni prostatektomiji brez ohranjanja živcev.

it is not known if cialis is effective in patients who have undergone pelvic surgery or radical non- nerve-sparing prostatectomy
ni znano, če je cialis učinkovit pri bolnikih po operacijah v medenici ali po radikalni prostatektomiji brez ohranjanja živcev.

it is not known if cialis is effective in patients who have undergone pelvic surgery or radical non-nerve- sparing prostatectomy.
ni znano, ali je zdravilo cialis učinkovito pri bolnikih po operacijah v medenici ali po radikalni prostatektomiji brez ohranjanja živcev.

it is not known if tadalafil lilly is effective in patients who have undergone pelvic surgery or radical non- nerve-sparing prostatectomy.
ni znano, ali je zdravilo tadalafil lilly učinkovito pri bolnikih po operacijah v medenici ali po radikalni prostatektomiji brez ohranjanja živcev.

one study was carried out in diabetic men and another in post-prostatectomy patients (men who have had their prostate gland removed).
v eno študijo so bili vključeni moški s sladkorno boleznijo, v drugo pa bolniki po prostatektomiji (operativni odstranitvi prostate).

bicalutamide is an oral-androgen used in the management of locally advanced prostate cancer, as an immediate therapy either alone or as adjuvant to treatment by radical prostatectomy or radiotherapy.
bikalutamid je peroralni antiandrogen, ki se uporablja pri zdravljenju lokalno napredovalega raka prostate, in sicer kot takojšnje samostojno zdravljenje ali kot dodatek k zdravljenju z radikalno prostatektomijo ali radioterapijo.

in a study involving patients with rising psa after localised therapy (mainly radical prostatectomy and radiation) were administered firmagon for seven months followed by a seven months monitoring period.
v študiji, ki je vključevala bolnike z naraščajočim psa po lokalnem zdravljenju (predvsem radikalni prostatektomiji in obsevanju), so bolniki sedem mesecev prejemali zdravilo firmagon, nato pa je sledilo sedemmesečno obdobje opazovanja.

therefore, clinicians may decide that the optimum medical strategy for a patient at low risk of disease progression, particularly in the adjuvant setting following radical prostatectomy, may be to defer hormonal therapy until signs that the disease is progressing.
zato se lahko zdravniki odločijo, da je optimalna medicinska strategija pri bolniku z majhnim tveganjem za napredovanje bolezni (zlasti v adjuvantnih okoliščinah po radikalni prostatektomiji) odložitev hormonskega zdravljenja, dokler se ne pojavijo znaki napredovanja bolezni.

in a clinical trial in post-prostatectomy patients, vardenafil significantly improved the erectile function domain score, the ability to obtain and maintain an erection long enough for successful intercourse and penile rigidity compared to placebo at vardenafil doses of 10 mg and 20 mg.
v kliničnem preskušanju pri bolnikih po prostatektomiji, v kateri so primerjali placebo z 10- in 20- miligramskimi odmerki vardenafila, je vardenafil pomembno izboljšal erektilno funkcijo, zmožnost doseganja in ohranjanja erekcije (omogočen je bil uspešen spolni odnos), ter otrdelost penisa.

across all trials, the proportion of patients reporting improvement on sildenafil were as follows: psychogenic erectile dysfunction (84 %), mixed erectile dysfunction (77 %), organic erectile dysfunction (68 %), elderly (67 %), diabetes mellitus (59 %), ischaemic heart disease (69 %), hypertension (68 %), turp (61 %), radical prostatectomy (43 %), spinal cord injury (83 %), depression (75 %).
v vseh študijah skupaj so bili deleži bolnikov, ki so s sildenafilom navajali izboljšanje, naslednji: psihogena erektilna disfunkcija (84 %), mešana erektilna disfunkcija (77 %), organska erektilna disfunkcija (68 %), starostniki (67 %), sladkorna bolezen (59 %), ishemična bolezen srca (69 %), zvišan krvni tlak (68 %), transuretralna resekcija prostate (61 %), radikalna prostatektomija (43 %), poškodba hrbtenjače (83 %), depresija (75 %).